Yttrium-90 Microspheres for Unresectable Metastatic Neuroendocrine Liver Tumors

Pretty good data. 41 months, not sure what SOC is.

http://onlinelibrary.wiley.com/doi/10.1111/jgh.13752/full

Abstract

Purpose

To assess the effectiveness of yttrium-90 (⁹⁰Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET).
Methods

From February 2006 to September 2015, 36 patients (19 male and 17 female, age, 63.6 ± 9.4 years) who underwent ⁹⁰Y therapy for unresectable liver metastases of NET were included and analyzed retrospectively. All patients received a variety of treatments prior to ⁹⁰Y therapy. The radiological response, symptoms improvement of carcinoid syndrome, tumor marker changes, complications, side effects/toxicity, survival and factors related to survival were evaluated and analyzed.
Results

Of the 36 patients, the mean delivered activity of ⁹⁰Y was 1.8 ± 0.7 GBq with a total of 40 treatments. Overall disease control rate was 88.9% (32/36) at 3 months following therapy. In 16 patients with carcinoid syndrome, 15 (93.8%) patients had symptomatic improvement. Tumor marker response (5-hydroxyindoleacetic acid [n = 7] and chromogranin A [n = 13]) at 3 months after treatment were: none (n = 0, 4), partial (n = 6, 7), and complete (n = 1, 2). Radiation-induced gastrointestinal ulcers (n = 2, 5.6%) were identified. Side effects included fatigue (n = 31, 86.1%), anorexia (n = 26, 72.2%), nausea (n = 15, 41.7%), vomiting (n = 14, 38.9%), abdominal pain (n = 10, 27.8%) and fever (n = 8, 22.2%). The mean follow-up was 27.0 ± 16.4 months, with a median survival of 41.0 months. Child-Pugh classification (P = 0.008) and lymph node metastases (P = 0.045) had statistically significant influence on overall survival.
Conclusions

⁹⁰Y radioembolization can be effective in the treatment of unresectable liver metastases of NET who failed to respond to other treatments.